The European Perspective
EU’s Biotech Gambit
Brussels’ pre-holiday legislative rush reveals a familiar pattern: policy favouring entrenched players. The EU’s new “Biotech Act,” published on December 16, is being framed as a win for public health, yet the fine print suggests a significant victory for the established pharmaceutical and food industries (Politico). While aiming to simplify regulations, the measures risk cementing the market power of large corporations. From my vantage point, this isn’t fostering a truly competitive landscape for agile startups. Instead, it looks like a classic case of regulatory capture, where complex rules become a moat protecting incumbents from the disruptive challengers who drive genuine progress. The real test is whether it can reverse the slide in Europe’s share of global clinical trials, which has already dropped from 25% to 19% in recent years (European Commission).
Milan’s Market Momentum
While Rome’s political class passed a contentious 2026 budget, Italian markets are sending a different signal. Milan’s FTSE Mib stock index—a benchmark for Italy’s 40 largest companies—surged 1.14% to close at 44,944 points, capping a year with over 30% gains, the best since 2000 (Ansa, MarketScreener). This rally suggests investor confidence that transcends political noise. More importantly, the BTP-Bund spread, a key gauge of Italy’s perceived credit risk versus Germany’s, held steady near 69 basis points (Ansa). A buoyant, capital-rich market is essential fuel for the tech ecosystem. This financial confidence could provide the firepower for Italy’s next wave of entrepreneurs, regardless of state intervention.
Catch the next Gist for the continent’s moving pieces.
|
Leave a Reply